Rivastigmine Tartrate NDC 62135-900

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-900Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0900Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-900-60	62135090060	60 CAPSULE in 1 BOTTLE (62135-900-60)Marketed from Jan 4, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rivastigmine Tartrate
Generic name (nonproprietary): rivastigmine tartrate
Active ingredients: Rivastigmine tartrate — 1.5 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207797
Marketing start: Sep 28, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Cholinesterase Inhibitors (Mechanism)
Identifiers: Product ID 62135-900_070bd281-9772-c587-e063-6294a90a04a2SPL ID 070bd281-9772-c587-e063-6294a90a04a2SPL set ID 2bb5e0d6-f677-4021-9888-3ff90979ef7dRxCUI 312835, 312836, 314214, 314215UNII 9IY2357JPEUPC 0362135901608, 0362135903602, 0362135902605, 0362135900601
Pharmacologic class: Cholinesterase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135090060 followed by a unit qualifier and the quantity

Package 62135-0900-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 6, 2023.

Indications (excerpt from the label)

Rivastigmine tartrate is an acetylcholinesterase inhibitor indicated for treatment of: Mild to moderate dementia of the Alzheimer’s type ( 1.1 ) Mild to moderate dementia associated with Parkinson’s disease ( 1.2 ) 1.1 Alzheimer's Disease Rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. 1.2 Parkinson’s Disease Dementia Rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207797

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207797
Product	Strength	Form · route	Labeler	Product NDC
Rivastigmine Tartrate	Rivastigmine tartrate 6 mg/1	CapsuleOral	Chartwell RX, LLC	62135-903
Rivastigmine Tartrate	Rivastigmine tartrate 3 mg/1	CapsuleOral	Chartwell RX, LLC	62135-901
Rivastigmine Tartrate	Rivastigmine tartrate 4.5 mg/1	CapsuleOral	Chartwell RX, LLC	62135-902